
Please try another search
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer and non-small cell lung cancer, as well as for liquid or solid tumors, appendiceal, colorectal and gastric cancers, other gynecologic malignancies, and peritoneal mesothelioma. The company has a licensing agreement with Newsoara BioPharma Co. Ltd. to research, develop, commercialize or exploit Olvi-Vec in China, including Mainland China, Taiwan, Hong Kong, and Macau, for human diagnostic, prophylactic, and therapeutic uses. Genelux Corporation was incorporated in 2001 and is headquartered in Westlake Village, California.
Name | Age | Since | Title |
---|---|---|---|
John Thomas | 65 | 2002 | Non-Employee Independent Director |
Mary Mirabelli | 66 | 2021 | Non-Employee Independent Director |
James Lee Tyree | 70 | 2012 | Lead Independent Director |
Thomas J. Herzog | - | - | Member of Clinical Advisory Board |
Robert W. Holloway | - | - | Member of Clinical Advisory Board |
Alberto A. Mendivil | - | - | Member of Clinical Advisory Board |
Alan B. Forsythe | - | 2023 | Member of Clinical Advisory Board |
Robert L. Coleman | 62 | - | Member of Clinical Advisory Board |
David M. O’Malley | - | - | Member of Clinical Advisory Board |
Thomas Zindrick | 64 | 2014 | Chairman, CEO & President |
John W. Smither | 71 | 2023 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review